Recon: Moderna eyes $50-60 price for COVID-19 vaccine; UK signs deal for Sanofi, GSK coronavirus vaccine

• Moderna pitches virus vaccine at about $50-$60 per course (Financial Times) (STAT)
• Moderna Vaccine Test in Monkeys Shows Promise (NYTimes)
• Most voters say they'd rather wait for an effective coronavirus vaccine (Politico)
• Public Health Experts Fear a Hasty FDA Signoff on Vaccine (KHN)
• ‘Nobody Likes Me,’ Trump Complains, Renewing Defense of Dubious Science (NYTimes)
• Trump says he still thinks hydroxychloroquine works in treating early stage coronavirus (CNBC) (AP)
• ‘This is health care moonshot time’: Pandemic pulls Biden, Dems further left (Politico)
• Pfizer chief says Trump price threats distract from vaccine progress (Financial Times)
• Lawmakers urge congressional watchdog to probe US government’s role in discovering remdesivir (STAT)
• Genentech to cut 474 Bay Area-based jobs (SF Chronicle)
• Amgen Reports Second Quarter 2020 Financial Results (Press)

• Roche bid to retool arthritis drug for COVID-19 fails (Reuters) (BioPharmaDive) (Press)
• UK 'must ensure medicines stockpile replenished' for Covid-19 second wave (The Guardian)
• UK strikes deal for 60m Covid-19 vaccine doses with Sanofi and GSK (Financial Times) (Press)
• ‘Silver bullet’ to beat Covid-19 unlikely, warns UK vaccine chief (Financial Times)
• Covid-19 hastens French push to bring home medicines manufacture (Financial Times)
• Indian API makers benefit as global buyers ditch China (Economic Times)
• Europe secures supply of Gilead's COVID-19 drug remdesivir (BioPharmaDive)
• Cepheid is accused of overcharging and undersupplying its Covid-19 test to poor countries (STAT)
• WHO, WIPO, WTO launch updated study on access to medical technologies and innovation (WHO)
• Sanofi lifts earnings view as Regeneron stake sale boosts Q2 (CNBC) (Press)
• GSK profit misses as vaccine sales disappoint, stockpiling eases (Reuters) (Press)

• The Coronavirus Could Dodge Some Treatments, Study Suggests (NYTimes)
• Harvested Antibodies Now Being Tested As A Prevention Tool Against COVID-19 (NPR)
• Remdesivir Could Be in Short Supply. Here’s a Fix. (NYTimes)
• US FDA’s Coronavirus Workload Shifting Beyond Idea Stage (Pink Sheet)
• Color targets supply, staffing bottlenecks with updated coronavirus test EUA (MedtechDive)
• Hologic wins HHS-DOD contract to boost COVID-19 test supplies production (MedtechDive)
• Sorrento picks up color-changing COVID-19 saliva test built by Columbia University fertility clinic (Fierce)
• Coronavirus (COVID-19) Update: Daily Roundup July 28, 2020 (FDA)

• Harry Reid and Alex Trebek tried Patrick Soon-Shiong’s experimental cancer therapy. Can their results be duplicated in a clinical trial? (STAT)
• Cancer drug is the first potential therapy to emerge from 23andMe and GlaxoSmithKline collaboration (STAT)
• GSK’s latest pipeline review includes a slate of COPD programs headed to the scrap heap (Endpoints) (Fierce)
• Sanofi prunes its pipeline, taking the ax to a lineup of drug, vaccine programs (Endpoints) (Fierce)
• Roche/Genentech doubles down on tau, fronting $120M cash to ally on a 2-pronged strategy to fight Alzheimer’s (Endpoints)
• Amgen tosses back unwanted bispecific to Xencor as KRAS data on track for 2020 readout (Fierce)
• Takeda poised to cut sales jobs in Japan as restructuring continues (Pharmafile)
• DSCSA Pilot Used Blockchain To Trace Drug Through 'Last Mile' of Supply Chain (Pink Sheet)
• Three years after leaving Biogen, Alpna Seth takes the spotlight with $73M for her neuro startup (Endpoints)
•  'Exquisite control': Flagship pulls off $85M rally around Omega Therapeutics' clinical push for epigenetic programming tech (Endpoints)
• Codiak gets a competitor, as Mantra Bio leaves stealth and enters growing exosome space (Endpoints)
• Which pharma advertising did President Trump lambaste on Twitter? Good question (Fierce)
• EC approves subcutaneous version of Remsima (PharmaTimes)
• Novartis receives Piqray® approval in Europe – the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation (Press)
• Opaque Pricing Could Protect Europe From US Policy (Pink Sheet)
• Industry Laments UK Change To SPC Waiver Approach (Pink Sheet)
• The secret life of excipients (Nature)
• Recursion Pharma acquires digital vivarium outfit Vium (Fierce)
• AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention (Press)

• Robot redux: Pandemic scrambles competitive timelines for Intuitive, J&J, Medtronic (MedtechDive)
• Dexcom nixes plan to begin G7 launch this year (MedtechDive)
• Medical devices provide another window for hospital hackers (Modern Healthcare)
• ‘Amazing, Isn’t It?’ Long-Sought Blood Test for Alzheimer’s in Reach (NYTimes)
• Framework for the evaluation of new tests for tuberculosis infection (WHO)
• Thrive flourishes, raises $257M to carry forward its cancer-seeking blood test (Fierce)
• LabCorp says COVID-19 testing 'more than' offsets still-recovering base business (MedtechDive)
• Smith+Nephew misses expectations in Q2 (MassDevice)
• Boston Scientific rises on Street-beating Q2 (MassDevice)
• LivaNova slides despite forecast-topping Q2 results (MassDevice)
• Dexcom up after hours on Street-beating Q2 (MassDevice)
• Baxter and Ayogo Announce Partnership for Unique Digital Health Solutions for Home Dialysis (Press)

• Genentech v. JHL case schedule extended (Big Molecule Watch)
• Up, Up and But Not Away: DEA Raises Registration Fees (FDA Law Blog)
• 6th Circ. Questions Opioid Negotiation Class 'Inventiveness’ (Law360)